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270 (IQR 96-457) at 2 years. In controls (n = 45) the values
were 367 (230-475) at baseline and 345 (IQR 245-455) at 2
vears. The difference in median levels at 2 years was statisti-
callv sianificant (P = 0.03).
5. The difference in fibre intake shown in Table 2 is not statisti-
cally significant. However. in the trial as a whole. when the
difference in fibre intake is the same but the number of
subjects is ofcourse much larger. the difference between inter-
vention and control groups is highly sianificant.
We thus find no evidence to support the suggestion that a higher
proportion of the intervention group was entering menopause at
baseline. However. it does seem that the main effect ofthe dietary
intervention on oestradiol levels may be in women over 45 years.
although this conclusion is based on small numbers and is obvi-
ouslv preliminary.
NBovd
Div-ision ofEpidemiology and Statistics. Ontario Cancer Institute,
Princess Margaret Hospital. Toronto. Ontario. Canada
Basal cell carcinoma of the face: surgery or
radiotherapy? Results of a randomized study
Sir,
I read with interest the recent paper by Avril et al ( 1997
describing the results of a prospective study comparing surgery
and radiotherapy in the management of basal cell carcinomas
(BCCs) of the face in 347 patients. Because both tumour recur-
rence rates and cosmesis were found to be significantly better in
the surgically managed group. the authors concluded that surgery
should be considered as the first-line treatment ofchoice for facial
BCCs less than 4 cm in diameter.
While there is undoubtedly a need for good randomized
prospective trials comparing the effectiveness ofthe two treatment
options. this study did not address the issues of management as
they are commonly encountered in current clinical practice. In the
study. the authors compared the treatment modalities in patients
with a wide range of clinical presentations. The size of tumours.
for example. ranged from 3-5 mm (10%c) to 31-40 mm (0.9%c) in
diameter. with 57%7c of tumours < 10 mm and 93%c <20 mm. Most
lesions were non-ulcerated nodules clinically. with a smaller
number of superficial (22%c) and morphoeic-type BCCs (4%7c). The
affected sites included the forehead. cheeks. chin. ears and nose.
It is perhaps these broad inclusion criteria that weakened the
overall value ofthe trial. One ofthe fundamental principles ofskin
cancer management is. wxhen possible. to completely remove
tumours (Flemingy et al. 1995). In practice. most dermatologists
would opt for excision of lesions if it were both technically
possible and likely to give good cosmetic results. As the majority
of BCCs in both treatment groups were < 1 cm in diameter. it
seems likelT that many of these tumours would have been
amenable to simple surgical excision with primary closure. In
those cases treated with radiotherapy. surgical intervention would
not only have avoided multiple outpatient visits. or even lengthy
inpatient stays. but would have permitted histological assessment
ofresection margins.
In their conclusions. the authors stated that. for facial BCCs less
than 4 cm in diameter. surgery is the treatment ofchoice. It is well
recognized that radiotherapy has a valuable role in the manage-
ment of particular clinical problems. such as tumours affectinc,
cartilaginous areas and the treatment of large ulcerated lesions
often encountered in elderly patients (Fleming et al. 1995). This
conclusion. while undoubtedly true for small lesions amenable to
excision. disregards the usefulness of radiotherapy in the manage-
ment oflarger and more awkwardly situated lesions.
Dr Susan Holmes
Department ofDermatologY,
University ofGlasgowz
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Expression of bcJl2 protein in follicular lymphomas:
a report from a south Indian hospital
Sir,
The t 14:18) translocation juxtaposes part of the immunoglobulin
heavy-chain gene on chromosome 14 with the bcl-2 gene on chro-
mosome 18. This translocation was discovered in most follicular-
centre cell lymphoma. The prevalance of t( 1418) shows a
geographical predilection. being highest in the USA and lowest in
Japan (Isaacson. 1991 ). The bcl-2 oncoprotein can be easily local-
ized using immunohistochemical staining. and this has been
studied in follicular lymphomas occumrng in the West. We
assessed the frequency of bcl-2 expression in follicular
lymphomas in 51 subjects from the Indian subcontinent.
Out of a total of 406 cases of non-Hodgkin's lymphoma diag-
nosed from 1 March 1995 to 30 September 1997. 55 were follic-
ular l-mphoma (1 3.5%). Formalin-fixed paraffin-embedded tissue
samples for immunohistochemistrv w-ere available in only 51 of
these cases. Immunohistochemical analysis was performed on
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deparaffimized sections using the avidin-biotin peroxidase tech-
nique and developed with diaminobenzidine (DAB) using a mono-
clonal antibody to the bcl-2 protein (Dako. Glostrup. Denmark).
The histological breakup of these 51 cases according to the
Working Formulation is as follows: 35 (68.6%) were small
cleaved-cell type. ten (19.6%) were mixed small- and large-cell
type and six (11.7%) large-cell type. bcl-2 reactivity was noticed
in 88.2% of all cases of follicular lymphomas. The breakup of
cases according to the histological subtype and the bcl-2 reactivity
is given in Table 1.
The incidence of follicular lymphoma is lower in the East
ranging from 7.4% in Taiwan to 13% in Hong Kong. Our
incidence of 13.5% is similar to these values.
According to Westem literature, approximately 85% of all
follicular lymphomas are immunohistochemically positive for
bcl-2 protein (Ngan et al, 1988: Wamke et al, 1991: Gaulard et al.
1992; Utz and Swerdlow, 1993). In the present study. 88.2% ofall
follicular lymphomas were immunohistochemically positive for
the bcl-2 protein. Among the histological subtypes of follicular
lymphomas, bcl-2 positivity in small cleaved-cell type has been
reported as being 100% (Gaulard et al, 1992) compared with
91.4% in our study. Actual numbers for bcl-2 reactivity in the
other two subtypes, mixed small- and large-cell and large-cell type
were too small to be compared with other studies.
Table 1 Results of bcd-2 reactMty in te histological subtypes of follicular
t4hr ma
Histmlogical type Positive casesinunber studied
Small cleaved cell 32/35 (91.4)
Mixed 8/10 (80)
Large cell 5/6 (83.8)
Total 45/51 (88.2)
Numbers in parentheses are percentages
Rearrangements of the bcl-2 gene have been studied in follic-
ular lymphoma in various countries. The incidence of this
rearrangement in patients with follicular lymphoma is higher in
the USA (60%). Taiwan (52.9%) and other Westem countries. but
is lower in Japan (33%) and Hong Kong (Chen et al. 1993). Future
studies detecting the presence ofthis gene rearrangement in follic-
ular lymphomas in India are required.
In conclusion, the frequency of bcl-2 protein expression in
follicular lymphomas in India is similar to that of other Westem
studies.
S Thomas and SNair
Department ofPathology
Christian Medical College Hospital
Vellore, India
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